Quick Answer
Kyverna Therapeutics, Inc. reported Net Income of -$161.31 million for fiscal year 2025.
Kyverna Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$161.31M -26.5% |
-$127.48M -111.2% |
-$60.37M | — |
| Diluted EPS | -$3.64 -9.3% |
-$3.33 +96.3% |
-$89.61 | — |
| Total Assets | $293.83M -3.6% |
$304.64M +305.1% |
$75.19M | — |
| Cash and Equivalents | $124.09M +28.4% |
$96.62M +178.9% |
$34.65M | — |
| Stockholders Equity | $232.28M -12.9% |
$266.59M +2129.0% |
-$13.14M +82.2% |
-$74.00M |
| R&D Expense | $133.72M +18.9% |
$112.47M +125.3% |
$49.92M | — |
| Operating Income | -$169.83M -19.1% |
-$142.60M -128.5% |
-$62.41M | — |
| Shares Outstanding | 60.39M +39.7% |
43.21M +3356.9% |
1.25M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$36.79M | -6.7% | +12.6% |
| Diluted EPS | September 30, 2025 | -$0.85 | -6.2% | +12.4% |
| Total Assets | September 30, 2025 | $187.16M | -44.8% | -17.4% |
| Cash and Equivalents | September 30, 2025 | $34.16M | -67.4% | -36.1% |
| Stockholders Equity | September 30, 2025 | $151.95M | -49.8% | -17.6% |
| R&D Expense | September 30, 2025 | $30.46M | +4.3% | -15.0% |
| Operating Income | September 30, 2025 | -$38.73M | +0.1% | +12.8% |
| Shares Outstanding | September 30, 2025 | 43.79M | +1.5% | +1.3% |
- Kyverna Therapeutics, Inc. reported Net Income of -$161.31 million for fiscal year 2025.
- Kyverna Therapeutics, Inc. showed a decrease of -26.5% in Net Income compared to the prior fiscal year.
- Kyverna Therapeutics, Inc. reported Diluted EPS of $3.64 per share (loss) for fiscal year 2025.
- Kyverna Therapeutics, Inc. showed a decrease of -9.3% in Diluted EPS compared to the prior fiscal year.
- Kyverna Therapeutics, Inc. reported Total Assets of $293.83 million for fiscal year 2025.
- Kyverna Therapeutics, Inc. showed a decrease of -3.6% in Total Assets compared to the prior fiscal year.
- Kyverna Therapeutics, Inc. reported Cash and Equivalents of $124.09 million for fiscal year 2025.
- Kyverna Therapeutics, Inc. showed an increase of +28.4% in Cash and Equivalents compared to the prior fiscal year.
- Kyverna Therapeutics, Inc. reported Stockholders Equity of $232.28 million for fiscal year 2025.
- Kyverna Therapeutics, Inc. showed a decrease of -12.9% in Stockholders Equity compared to the prior fiscal year.
- Kyverna Therapeutics, Inc. reported R&D Expense of $133.72 million for fiscal year 2025.
- Kyverna Therapeutics, Inc. showed an increase of +18.9% in R&D Expense compared to the prior fiscal year.
- Kyverna Therapeutics, Inc. reported Operating Income of -$169.83 million for fiscal year 2025.
- Kyverna Therapeutics, Inc. showed a decrease of -19.1% in Operating Income compared to the prior fiscal year.
- Kyverna Therapeutics, Inc. reported Shares Outstanding of 60.39 million shares for fiscal year 2025.
- Kyverna Therapeutics, Inc. showed an increase of +39.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: